Associations - KRAS amplification

BIOMARKER:

KRAS amplification

Entrez ID:

Related biomarkers:

‹

›

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

KRAS amplification KRAS amplification	Melanoma Melanoma	sorafenib Sensitive: B - Late Trials sorafenib Sensitive : B
KRAS amplification KRAS amplification	Colorectal Cancer CRC	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3
KRAS amplification KRAS amplification	Colorectal Cancer CRC	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3
KRAS amplification KRAS amplification	Colorectal Cancer CRC	panitumumab Resistant: C3 – Early Trials panitumumab Resistant : C3
KRAS amplification KRAS amplification	Germ Cell Tumors Germ Cell Tumors	MEK inhibitor Sensitive: C3 – Early Trials MEK inhibitor Sensitive : C3
KRAS amplification KRAS amplification	Non Small Cell Lung Cancer NSCLC	lorlatinib Resistant: C3 – Early Trials lorlatinib Resistant : C3
KRAS amplification KRAS amplification	Pancreatic Cancer Pancreatic Cancer	binimetinib Resistant: D – Preclinical binimetinib Resistant : D